Why Stratasys (SSYS) Stock Is Jumping Today

NEW YORK (TheStreet) -- Stratasys (SSYS) was gaining 15.9% to $114.59 Thursday after beating analysts' estimates for the second quarter and guiding above estimates for the year.

The 3D printer maker reported earnings of 55 cents a share for the second quarter, beating the Capital IQ Consensus Estimate of 44 cents a share by 11 cents. Revenue grew 67.6% from the year-ago quarter to $187.5 million. Analysts expected revenue of $156.97 million for the quarter.

Stratasys said it expects earnings of $2.25 to $2.35 a share for the full year, above analysts' estimates of $2.18 a share. The company expects revenue of $750 million to $770 million for full year 2014, above analysts' estimates of $688.49 million.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates STRATASYS LTD as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate STRATASYS LTD (SSYS) a HOLD. The primary factors that have impacted our rating are mixed ? some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we find that the company's return on equity has been disappointing."

If you liked this article you might like

These Stocks Are Changing Course

Analysts' Actions -- Citizens Financial, Expedia, First Solar, Jack in the Box and More

Stratasys Stock Drops Premarket Despite 4Q Beat

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)